Latest Syncytium Stories
New therapies are needed to prevent and treat respiratory syncytial virus (RSV) – a potentially lethal respiratory infection that can severely affect infants, young children and the elderly.
Researchers at the University of Toronto, The Hospital for Sick Children (SickKids), St. Paul's Hospital and the University of British Columbia have identified a new treatment target for a virus that causes severe lung infections and an estimated 10% of common colds.
GAITHERSBURG, Md., May 3 /PRNewswire/ -- MedImmune, the global biologics unit of AstraZeneca, announced today that researchers will present results from five studies in the areas of respiratory syncytial virus (RSV) at the 2010 Pediatric Academic Societies (PAS) annual meeting taking place May 1-4, 2010 in Vancouver, BC, Canada.
MORGANTOWN, W.Va., Sept. 4 /PRNewswire-USNewswire/ -- Approximately one-half of all infants are infected with the respiratory syncytial virus (RSV) during the first year of life, and almost all children have been infected at least once by the time they reach their second birthday.
Researchers from Durham University's Centre for Bioactive Chemistry are developing methods that show how proteins interact with cell membranes when a virus strikes.
U.S. researchers said on Wednesday that a highly contagious respiratory virus is far more widespread among children than once thought and puts more of them in the hospital than influenza.
Respiratory syncytial virus (RSV) causes respiratory tract infections and is a major cause of lower respiratory tract infection and hospital visits during infancy and childhood. For premature infants and infants with congenital heart disease there is a prophylactic medication. During winter months in temperate climates there is an annual epidemic. Infection in tropical climates is most common during the rainy season. 60% of infants, in the United States, are infected during their first...